1. Introduction {#sec1}
===============

Craniofrontonasal syndrome (CFNS; *OMIM \# 304110*) \[[@B1]\] is an X-linked syndrome involving developmental malformation with variable clinical expression characterized by severe hypertelorism, depressed nasal bridge and bifid nasal tip, frontal bossing, coronal suture synostosis, corpus callosum agenesis, and occasionally cleft lip or palate \[[@B2]--[@B4]\]. This disorder is caused by mutations in the *EFNB1* gene, located at Xq13.1, and encoding a ligand of the Ephrin family of receptor protein tyrosine kinases \[[@B3]\]. The most common types of *EFNB1*mutations (up to 55%) in CFNS patients are frameshift, nonsense, and splice site mutations that lead to premature termination codons (PTCs). Missense mutations constitute approximately 42% of all *EFNB1*mutations, and most of them occur in exons 2 and 3, leading to the substitutions of amino acid residues involved in receptor-ligand interaction and cell signaling, which are critical for cell sorting, migration and adhesion, midline fusion, axon guidance, neural plasticity, and synaptogenesis \[[@B5]--[@B8]\]. Here, we describe a sporadic case of CFNS due to a novel *EFNB1* mutation occurring in a female Mexican patient.

2. Case Presentation {#sec2}
====================

A 3-month-old girl was referred to the Genetics Department after a frontoorbital advancement surgery due to right unicoronal synostosis and facial dysmorphism. She is the only child of healthy, nonconsanguineous parents. There was no prenatal exposure to teratogenic agents. A structural ultrasound at 24 weeks revealed a nonspecific cranial malformation. The patient was delivered by caesarean section at 38 weeks of pregnancy and had a birth weight of 2,700 g, birth length of 48.5 cm, and an Apgar score of 8/9. Birth examination disclosed plagiocephaly (left frontal bossing and right coronal synostosis), hypertelorism, downslanting palpebral fissures, facial asymmetry, a broad and flattened nasal bridge, a bifid nasal tip, and broad thumbs and halluces with longitudinally split nails ([Figure 1](#fig1){ref-type="fig"}). No abnormalities were found in the transfontanellar ultrasound and echocardiogram performed during the first week of life. Cytogenetic study was normal (46,XX\[25\]). When the patient reached the age of 3 months, cranial computerized tomography (CT) revealed right coronal synostosis and mild compression of the surrounding cerebral parenchyma, which prompted surgery. At present, she has reached adequate development milestones and growth parameters.

After obtaining local ethics institutional approval and the informed consent of her parents, genomic DNA was extracted from the patient\'s peripheral blood leukocytes using a semiautomated Quickgene system (Fujifilm, Tokyo, Japan). The complete *EFNB1* coding sequence, including the exon-intron boundaries, was amplified by PCR using primers for the 5 exons ([Table 1](#tab1){ref-type="table"}), and direct automated sequencing was performed using the Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, California, USA) in an ABI Prism 3130 Genetic Analyzer (Applied Biosystems).

Nucleotide analysis disclosed a novel heterozygous transition c.473T\>C in exon 3 of *EFNB1*. This mutation predicted a substitution of methionine (ATG) to threonine (ACG) in the extracellular domain of the protein (p.M158T) ([Figure 2(a)](#fig2){ref-type="fig"}). Both parents had a normal sequence (Figures [2(b)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}).

3. Discussion {#sec3}
=============

Our report discussed a patient with clinical characteristics consistent with CNFS and in whom a novel *de novo EFNB1* mutation was demonstrated. CFNS shows a phenotypic pattern not usually seen in X-linked disorders, as heterozygous females are more severely affected than hemizygous males. Mutations in *EFNB1*are the cause of CFNS in the majority of patients, with a mutation detection rate of 92% \[[@B9], [@B10]\]. CNFS\'s clinical manifestations are sex dependent, with multiple skeletal malformations in affected females and mild or no malformations in male carriers. Recently, the severe phenotype in females has been explained through the cellular interference hypothesis; cellular interference is caused by the combination of Ephrin ligand/receptor promiscuity and the consequences of random X inactivation in distinct cellular compartments \[[@B3], [@B11]\]. Although we have identified a novel *de novo* mutation, no other new clinical features were found in the physical examination.

The*EFNB1*gene encodes Ephrin-B1 protein, a member of the ephrin family of transmembrane ligands for Eph receptors with tyrosine kinase activity. These proteins play a crucial role in cell migration and pattern formation during embryonic development \[[@B12]\]. Missense mutations, such as that demonstrated in our patient, constitute about 42% of *EFNB1* mutations. There are non-*hotspot* mutations in *EFNB1*gene; however, most of reported substitutions occur in the extracellular domain, which is encoded by exons 2 and 3, leading to a change in amino acid residues, which are important for receptor-ligand interaction and signaling, and cause loss of function \[[@B7]\].

The replacement from a hydrophobic sulfur amino acid such as methionine for a hydrophilic amino acid, threonine, modifies the polarity of the protein. *In silico* analysis of this novel missense *EFNB1* mutation using *PolyPhen-2* software indicated that this change is pathogenic ([Figure 3(a)](#fig3){ref-type="fig"}) and predicted to be highly conserved in different species ([Figure 3(b)](#fig3){ref-type="fig"}) \[[@B13]\]. The fact that this nucleotide substitution-transition was not found in the NHLBI Exome Sequencing Project (ESP; Exome Variant Server) supports the novel condition of our mutation \[[@B14]\].

In conclusion, we presented a patient with craniofrontonasal syndrome due to a novel *de novo* heterozygous transition mutation c.473T\>C in exon 3 of *EFNB1*. Our results expand the *EFNB1* mutational spectrum in CNFS patients. The M158 residue (methionine) of the Ephrin-B1 protein is highly conserved between species.
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![(a) Patient\'s facial appearance. Hypertelorism, broad and flattened nasal bridge, and bifid nasal tip are evident. (b) Broad toes with longitudinally split nails can be observed.](CRIM.GENETICS2013-349725.001){#fig1}

![Partial nucleotide sequence of the *EFNB1* gene in DNA from patient (a), proband\'s mother (b), and proband\'s father (c). (a) A heterozygous T to C transition at nucleotide position c.473 in exon 3 predicting a methionine (ATG) to threonine (ACG) replacement at residue 158 (p.M158T) is shown. (b and c) Normal nucleotide (T) in both parents.](CRIM.GENETICS2013-349725.002){#fig2}

![*In silico* analysis using *PolyPhen-2* software shows that change in p.M158T is pathogenic (a) and predicted to be highly conserved in different species (b).](CRIM.GENETICS2013-349725.003){#fig3}

###### 

PCR and sequencing primers for *EFNB1*.

  Primer name   5′-3′ orientation       Length of PCR product (bp)
  ------------- ----------------------- ----------------------------
  EFNB1-ex1-F   AAGGCGAGGCGAGCTTTGGT    318
  EFNB1-ex1-R   AAGCCGGAGACAAAATGAGG     
  EFNB1-ex2-F   TTGTCCGCTTCCCTGGTTCT    445
  EFNB1-ex2-R   ATTGCACCACTTAGAAGCTCC    
  EFNB1-ex3-F   GCTGAAGCAGAATGGGAGTT    246
  EFNB1-ex3-R   GCCAGGAACATCTGTTCCAA     
  EFNB1-ex4-F   GGTTACAGTATCCAGGCCAT    312
  EFNB1-ex4-R   GCCCAGCTTGCATTTCTTCA     
  EFNB1-ex5-F   TGAAGAAATGCAAGCTGGGC    606
  EFNB1-ex5-R   ATACAAAGGTGGGCACAGCT     
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